실시간
FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesLonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesEndpoints NewsParabilis Medicines charts $413M IPO to back peptide pipelineFierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADCPharmaVoiceHouse bill aims to crack down on China biotech dealsPharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problemsFierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’BioWorldFDA clears Shionogi’s Xocova as first COVID-19 prevention pillBrukerBruker showcases expanded microbiology diagnostics portfolio - Investing.comBrukerBruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報
이 기사는 아카이브에서 찾을 수 없습니다.